









Markets
/
Stocks
/
nasdaq-hoth
/

Hoth Therapeutics Inc

HOTH

1.800USD

-0.120-6.25%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

23.82MMarket Cap

LossP/E TTM



Hoth Therapeutics Inc

1.800

-0.120-6.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

114 / 175

Overall Ranking

410 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+108.33%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Undervalued

The company’s latest PE is -1.68, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 380.38K shares, decreasing 33.92% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 38.80K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -1.79, which is -53.97% below the recent high of -0.83 and 33.70% above the recent low of -1.19.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 114/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Hoth Therapeutics Inc is 4.00, with a high of 4.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Buy

Current Rating

4.000

Target Price

+108.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Hoth Therapeutics Inc

HOTH

Biogen Inc

BIIB

Amgen Inc

AMGN

Alnylam Pharmaceuticals Inc

ALNY

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.47, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 2.18 and the support level at 1.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.47

Change

-0.25

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.093

Buy

RSI(14)

66.798

Neutral

STOCH(KDJ)(9,3,3)

81.281

Neutral

ATR(14)

0.169

Low Volatility

CCI(14)

98.020

Neutral

Williams %R

20.270

Buy

TRIX(12,20)

1.506

Buy

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.823

Sell

MA10

1.686

Buy

MA20

1.475

Buy

MA50

1.375

Buy

MA100

1.227

Buy

MA200

1.134

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 2.88%, representing a quarter-over-quarter increase of 2.08%. The largest institutional shareholder is The Vanguard, holding a total of 38.80K shares, representing 0.29% of shares outstanding, with 47.93% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Knie Robb

58.13K

Geode Capital Management, L.L.C.

113.50K

+18.30%

UBS Financial Services, Inc.

58.76K

+89.58%

The Vanguard Group, Inc.

Star Investors

38.80K

Foundations Investment Advisors, LLC

15.00K

Two Sigma Investments, LP

28.29K

-34.66%

Morgan Stanley Smith Barney LLC

10.01K

Tower Research Capital LLC

1.64K

-63.04%

Pavell (Jeff)

5.08K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.